Group 1 - The company Sinopharm (01801) announced the granting of stock options and restricted shares to a total of 1,374 participants, including directors, under the 2024 share plan [2] - Specifically, 1.9356 million stock options were granted to 66 participants, while 10.2413 million restricted shares were granted to 1,308 participants, pending acceptance by the grantees [2]

Investment Rating - The report maintains an "Outperform" rating for Innovent Biologics [2] Core Insights - Innovent Biologics achieved total revenue of RMB 13.0 billion in FY25, representing a year-on-year growth of 38%, with product sales revenue reaching RMB 11.9 billion, up 45% [3][15] - The company turned a net profit attributable to shareholders of RMB 810 million in FY25, compared to a loss of approximately RMB 100 million in the previous year [3][15] - The gross margin improved to 86.5%, an increase of 2.6 percentage points year-on-year [3][15] - The report highlights strong organic sales growth driven by the oncology franchise and the expansion of the product portfolio, with multiple products included in the National Reimbursement Drug List (NRDL) expected to further boost sales in 2026 [4][16] - Out-licensing revenue of RMB 957 million was recognized in FY25, with significant upfront payments from collaborations with Roche and Takeda expected to be progressively recognized in the financial statements from 2026 onward [5][17] - The core asset IBI363 (PD-1/IL-2) is advancing smoothly, with three assets entering global Phase III clinical trials, estimated to have a combined addressable market exceeding USD 60 billion [7][19] - The early-stage pipeline shows strong global competitiveness, with 11 new molecules advanced into clinical development, expected to yield early data in 2026-2027 [9][20] - The target price is adjusted to HKD 107.40 based on a DCF model, reflecting an increase in revenue and net profit forecasts for 2026 and 2027 [10][21]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][15] Core Insights - The company achieved total revenue of 13.042 billion HKD in 2025, representing a year-on-year growth of 38.4%. Product sales revenue reached 11.896 billion HKD, up 44.6% year-on-year. The company reported a net profit of 814 million HKD under IFRS, compared to a loss of 95 million HKD in 2024, and a Non-IFRS net profit of 1.723 billion HKD. This growth is attributed to the leading position in oncology products and rapid expansion in cardiovascular and metabolic product lines. The company has also entered a global strategic collaboration with Takeda Pharmaceutical, which will gradually confirm high upfront payments in the coming years. The profit forecasts for 2026-2027 have been raised, with expected net profits of 2.178 billion HKD, 2.504 billion HKD, and 2.960 billion HKD for 2026, 2027, and 2028 respectively, leading to a current price-to-earnings ratio of 77.0, 67.0, and 56.6 times [6][10]. Financial Summary - The company’s total revenue is projected to reach 18.515 billion HKD in 2026, with a year-on-year growth of 42.0%. The net profit is expected to increase to 2.178 billion HKD, reflecting a growth of 167.7% compared to 2025. The gross margin is anticipated to be 86.8%, and the net margin is expected to be 11.8% [10][12]. Global Expansion and Innovation - The company is accelerating its global layout, with multiple innovative pipelines entering global MRCT. The core product IBI363 has initiated a global MRCT Phase III clinical study for IO-resistant squamous NSCLC. IBI343 has received two BTD designations from NMPA and FTD from the FDA, with its first international Phase III study for third-line gastric cancer ongoing in China and Japan. IBI324 is expected to start an international Phase III clinical study in 2026 [7][8]. Future Product Pipeline - The next-generation pipeline focuses on oncology with IO+ADC technologies, including IBI363, IBI343, IBI3003, bispecific ADCs, and dual payload ADCs. These aim to enhance treatment standards or address unmet needs in various fields. Several pipelines are currently in international Phase I clinical studies [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company achieved total revenue of 13.042 billion HKD in 2025, marking a year-on-year growth of 38.4%. Product sales revenue reached 11.896 billion HKD, up 44.6% year-on-year. The company reported a net profit of 814 million HKD under IFRS, compared to a loss of 95 million HKD in 2024. Non-IFRS net profit was 1.723 billion HKD. The growth is attributed to the company's leading position in oncology products and the rapid expansion of its cardiovascular and metabolic product lines [6][10] - The company has accelerated its globalization strategy, with key products entering global multi-regional clinical trials (MRCT). The core product IBI363 has initiated a global MRCT Phase III clinical study, while IBI343 has received breakthrough therapy designation (BTD) from NMPA and fast track designation (FTD) from the FDA [7][8] - The company has a strong pipeline focusing on innovative therapies in oncology, with multiple products expected to enter international Phase I clinical trials. The next-generation pipeline includes IBI363, IBI343, and others, aimed at addressing unmet medical needs [8] Financial Summary - In 2025, the company achieved a total revenue of 13.042 billion HKD, with a year-on-year growth of 38.4%. The projected revenues for 2026 and 2027 are 18.515 billion HKD and 21.515 billion HKD, respectively [10] - The net profit for 2026 is projected to be 2.178 billion HKD, with further growth expected in subsequent years, reaching 2.504 billion HKD in 2027 and 2.960 billion HKD in 2028 [10] - The company's gross margin is expected to remain high, with projections of 86.8% in 2026 and 86.6% in 2027 [10]

Core Viewpoint - Cinda Biologics is expected to report strong performance in the fiscal year 2025, achieving a net profit of 834 million yuan for the first time, with total revenue reaching 13 billion yuan, representing a year-on-year growth of 38% [1] Financial Performance - Total revenue for Cinda Biologics is projected to be 13 billion yuan, reflecting a year-on-year increase of 38% [1] - Product sales are anticipated to reach 11.9 billion yuan, marking a year-on-year growth of 45% [1] - The company is set to record its first annual net profit of 834 million yuan [1] Investment Outlook - The strong product line innovation capability and global development potential of Cinda Biologics support its transformation into a global biopharmaceutical company [1] - The investment rating for Cinda Biologics is maintained at "Buy," with the target price slightly increased from 110.62 HKD to 113.86 HKD [1]

Core Viewpoint - Cinda Biologics (01801.HK) is expected to report strong performance in the fiscal year 2025, achieving a net profit of 834 million RMB for the first time [1] Financial Performance - Total revenue reached 13 billion RMB, representing a year-on-year growth of 38% [1] - Product sales amounted to 11.9 billion RMB, reflecting a year-on-year increase of 45% [1] Investment Outlook - The company is recognized for its strong product innovation capabilities and global development potential, accelerating its transformation into a global biopharmaceutical player [1] - The investment rating for Cinda Biologics is maintained at "Buy," with the target price slightly increased from 110.62 HKD to 113.86 HKD [1]

Group 1 - The core announcement is that the company, Sinopharm (01801.HK), granted a total of 1,935,600 stock options to 66 grantees, including directors, under the 2024 share plan [1] - Additionally, the company awarded 10,241,300 restricted shares to 1,308 grantees, pending acceptance by the grantees [1]

Core Viewpoint - The company, Sinopharm (01801), announced the granting of stock options and restricted shares as part of its 2024 share plan, involving a total of 1,217,690 stock options and 10,241,300 restricted shares to various grantees, pending acceptance [1] Group 1 - The company granted 1,935,600 stock options to 66 grantees, including directors [1] - The company also granted 10,241,300 restricted shares to 1,308 grantees [1] - The grants are subject to acceptance by the grantees [1]

授出購股權 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 信達生物製藥 INNOVENT BIOLOGICS, INC. （於開曼群島註冊成立的有限公司） （股份代號：1801） 授出購股權及受限制股份 本公告乃根據上市規則第17.06A、17.06B及17.06C條而作出。董事會宣佈，於 2026年3月30日，本公司根據2024年股份計劃的條款向66名承授人（包括董事）授 出1,935,642份購股權（「授出購股權」）並向1,308名承授人授出10,241,272股受限 制股份（「授出受限制股份」），惟須待承授人接納。 授予承授人的購股權詳情如下： 授出日期： 2026年3月30日 承授人數目： 66名，其中58名為本集團非關連僱員（包括 高級管理層）及8名董事（詳情載於下文） 授出購股權數目： 1,935,642 於授出的購股權獲行使時 將予認購的新股份總數： 授出購股權的代價： 各承授人於接納授出的購股權時應支付1.00 港元 1 1,935 ...

Core Viewpoint - The company is expected to achieve strong revenue and profit growth in 2025, with total revenue projected at 13.042 billion yuan, a year-on-year increase of 38.4%, and product revenue at 11.896 billion yuan, up 44.6% [1][2] - The company has established significant partnerships with Roche, Takeda, and Eli Lilly, highlighting its strong R&D capabilities and increasing international recognition [1] - The company is becoming a leading pharmaceutical enterprise in China, with a competitive global innovation pipeline, and aims to become a world-class biopharmaceutical company [1] Financial Performance - In 2025, the company reported total revenue of 13.042 billion yuan, a 38.4% increase year-on-year, with product revenue reaching 11.896 billion yuan, up 44.6% [1] - The company achieved a turnaround in IFRS net profit, reporting 814 million yuan in 2025, a significant improvement from a loss of 95 million yuan in 2024, driven by strong revenue growth and improved operational efficiency [1] - Non-IFRS net profit for 2025 was 1.723 billion yuan, a substantial increase from 332 million yuan in 2024, with EBITDA reaching 1.99 billion yuan, up from 412 million yuan in 2024 [1] Commercialization and Product Development - The company has built a leading oncology brand in China and is developing a rising chronic disease innovation brand, with a comprehensive product portfolio and a mature commercialization network [2] - The product portfolio has expanded to 18 products, with 12 included in the national medical insurance, covering oncology, metabolism, and autoimmune diseases [2] - The company’s product revenue of 11.896 billion yuan in 2025 marks its first breakthrough of 10 billion yuan, reflecting the foresight and efficient commercialization execution, with expectations to exceed 20 billion yuan in product revenue by 2027 [2]